EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A year in pharmacology: new drugs approved by the US food and drug administration in 2025

Gizem Kayki-Mutlu, Zinnet Sevval Aksoyalp, Leszek Wojnowski, Martin C Michel

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-05 · 399 (8) · 11157-11179

DOI: 10.1007/s00210-026-05193-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 11.03.2026. Verfasst von Gizem Kayki-Mutlu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Türkiye. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsmedizin der Johannes Gutenberg-Universität Mainz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US Food and Drug Administration approved 45 new drugs and 4 new cellular and gene therapy products in 2025, that is, a total of 49 new medical therapies. Oncology, hematology/immunotherapy, and cardiovascular/respiratory drugs remain most frequent. Among oncology drugs, there is a trend for targeting ever smaller subtypes of malignancies and/or rarer malignancies. Trends over the past 6 years include steady levels of first-in-indication (about 10%), first-in-class (about 38%), and next-in-class (about 51%) approvals. Along with a large share of approvals in orphan indications (> 50%), fast track approval pathways are now regularly representing more than half of all new approvals. While small molecules remain the bedrock of novel medical treatments (about 60%), there is a growing segment of mRNA, gene, and cell-based pharmacological approaches. These data testify to the innovative strength of academia, biotechnology, and established pharmaceutical companies in providing innovative treatments, often related to previously unmet medical needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalUnited StatesHumansUnited States Food and Drug AdministrationAnimals

Stichwörter der Autor:innen

Cell-based therapyFirst-in-classGene therapyMonoclonal antibodyNew drugsNext-in-classOrphan drugsRare diseases

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Türkiye.
  • Department of Pharmacology, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir, Türkiye.
  • Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
  • Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany. marmiche@uni-mainz.de.
  • Pharmaceutical Medicine, Charlotte Fresenius University, Wiesbaden, Germany. marmiche@uni-mainz.de.

Förderung

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Zitieren

APA

Kayki-Mutlu, G., Aksoyalp, Z. S., Wojnowski, L., & Michel, M. C. (2026). A year in pharmacology: new drugs approved by the US food and drug administration in 2025. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(8), 11157-11179. https://doi.org/10.1007/s00210-026-05193-0

Vancouver

Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC. A year in pharmacology: new drugs approved by the US food and drug administration in 2025. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(8):11157-11179. doi:10.1007/s00210-026-05193-0

BibTeX
@article{KaykiMutlu2026,
  author = {Kayki-Mutlu, Gizem and Aksoyalp, Zinnet Sevval and Wojnowski, Leszek and Michel, Martin C},
  title = {A year in pharmacology: new drugs approved by the US food and drug administration in 2025},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  volume = {399},
  number = {8},
  pages = {11157--11179},
  doi = {10.1007/s00210-026-05193-0}
}
Kostenlos starten →